Swarali Tadwalkar
Principal Consultant
Swarali has over 9 years of experience in providing consultancy support for the design and implementation of market sizing, epidemiology and real-world studies. Swarali has led multiple projects across a wide array of therapy areas, including rare diseases, oncology, and metabolic disorders. Swarali acts as a project lead/manager for projects involving data collation, epidemiology analysis, market sizing strategies, data forecasting and deriving insights from various real-world data assets. She supports clients in various aspects, such as developing strategies to understand disease market, meeting preparation and development of evidence dossiers/briefing books for FDA/EMA submissions. Throughout her career, she has developed a strong interest in tackling data challenges for analyzing complex disease indications and deriving robust insights especially for rare diseases.
Swarali has presented epidemiology forecasts and results from real-world data studies at various conferences, including, the World Cancer Congress and the Indian Cancer Congress. She holds an MPH degree from the University of South Florida, Tampa specializing in Epidemiology and Biostatistics and a BE in Biotechnology from the University of Mumbai.
Latest news
Clarivate Scales Agentic AI Across Cortellis to Advance Drug Development
Expanded capabilities across Cortellis portfolio help life sciences organizations turn trusted intelligence into action and accelerate decision making across the research and development lifecycle London, U.K. — August 6, 2026— Clarivate…
Clarivate Companies to Watch Report Spotlights Seven Innovators Shaping the Next Generation of Obesity Therapies
New report examines novel mechanisms and emerging approaches advancing obesity treatment beyond today’s GLP-1 therapies London, U.K., August 5, 2026 — Clarivate Plc (NYSE:CLVT), a leading global provider of transformative…
Clarivate Appoints Michael Easton as Chief Financial Officer
Experienced Clarivate leader brings more than 25 years of financial and operational expertise LONDON, July 29, 2026: Clarivate Plc (NYSE: CLVT) (“Clarivate” or the “Company”), a leading global provider of transformative intelligence, today…
